This company is playing chess moves and you are observing from the checkers bench.
Company is playing chess moves?
Yeah, that is definitely not happening. A small microcap biotech isn't playing "chess moves" for a better deal.
That Canary's deal was a distraction, a strategical move to juicy up the bids on a buyout deal.
A strategical move? Juicy up bids on a buyout deal?
He entered into an agreement with Canary/Cornell to then terminate the deal in order to juicy up the bids for a buyout?
Are you serious?
EVERYONE KNEW, EVEN KINDERGARDEN KIDS COULD TELL REGEN DIDN'T HAVE THE 50M TO PULL IT OFF!!!
So, now people know they couldn't pull it off? Funny, I have been reading this board since this deal came about and not one person other than a few here said it wouldn't come to fruition.
But not only that, Regen was looking for the $50 million from an outside party... of course Regen themselves did not have the money.
So I am not sure what you are talking about here.
KOOS is a seasoned mate, he is a chess player, FOR THE RECORD: I have seen others companies cancelling LOI before, IT IS NORMAL!!! Please go and search what LOI means, it is not guarantee, there are a lot of details, questions, variables in the equation when it comes to negotiations like this, anything can go wrong. IT IS NORMAL TO SAY NO TO A DEAL LIKE THIS...
No. Just no.
You don't say NO to a deal with Cornell. Especially a struggling microcap biotech with no track record, trust or reputation.
There is nothing that Regen would turn down and nothing Cornell/Canary would ask that is unreasonable.
A revenue stream is a revenue stream. Simple as that.
BUYOUT OR MERGER THEORY IS STRONGER NOW THAN EVER...
There is nothing to buyout.
If you mean a partnership or collaboration with a stronger biotech or pharma company... then yes.